JP2013545752A - ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 - Google Patents

ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 Download PDF

Info

Publication number
JP2013545752A
JP2013545752A JP2013538998A JP2013538998A JP2013545752A JP 2013545752 A JP2013545752 A JP 2013545752A JP 2013538998 A JP2013538998 A JP 2013538998A JP 2013538998 A JP2013538998 A JP 2013538998A JP 2013545752 A JP2013545752 A JP 2013545752A
Authority
JP
Japan
Prior art keywords
genistein
formulation
subject
formulation according
nanoparticulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013538998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545752A5 (enExample
Inventor
ジョセフ エルダー，エドモンド
ジョセフ サチェッティ，マーク
ジョセフ タラチャク，ランダル
エル． ゼンク，ジョン
Original Assignee
ヒューマネティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヒューマネティクス コーポレイション filed Critical ヒューマネティクス コーポレイション
Publication of JP2013545752A publication Critical patent/JP2013545752A/ja
Publication of JP2013545752A5 publication Critical patent/JP2013545752A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
JP2013538998A 2010-11-15 2011-11-15 ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 Pending JP2013545752A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/946,711 2010-11-15
US12/946,711 US8900635B2 (en) 2010-11-15 2010-11-15 Nanoparticle isoflavone compositions and methods of making and using the same
PCT/US2011/060829 WO2012068140A1 (en) 2010-11-15 2011-11-15 Nanoparticle isoflavone compositions & methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015220365A Division JP6181733B2 (ja) 2010-11-15 2015-11-10 ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法

Publications (2)

Publication Number Publication Date
JP2013545752A true JP2013545752A (ja) 2013-12-26
JP2013545752A5 JP2013545752A5 (enExample) 2014-11-20

Family

ID=46047969

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013538998A Pending JP2013545752A (ja) 2010-11-15 2011-11-15 ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法
JP2015220365A Active JP6181733B2 (ja) 2010-11-15 2015-11-10 ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法
JP2017140477A Pending JP2018008967A (ja) 2010-11-15 2017-07-20 ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015220365A Active JP6181733B2 (ja) 2010-11-15 2015-11-10 ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法
JP2017140477A Pending JP2018008967A (ja) 2010-11-15 2017-07-20 ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法

Country Status (6)

Country Link
US (9) US8900635B2 (enExample)
EP (1) EP2640188B1 (enExample)
JP (3) JP2013545752A (enExample)
CA (1) CA2852410C (enExample)
IL (1) IL226377B (enExample)
WO (1) WO2012068140A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537430A (ja) * 2013-11-26 2016-12-01 ヒューマネティクス コーポレーション 生理学的に活性なフェノール化合物の懸濁組成物並びにそれを作製及び使用する方法
WO2018168777A1 (ja) * 2017-03-13 2018-09-20 学校法人関西学院 嚢胞性線維症予防又は治療剤
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900635B2 (en) * 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
US9623003B1 (en) 2013-04-04 2017-04-18 Humanetics Corporation Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
US9623004B2 (en) 2013-08-02 2017-04-18 Humanetics Corporation Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy
US20150126597A1 (en) * 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
US20170000761A1 (en) * 2013-11-27 2017-01-05 Humanetics Corporation Protecting tissue and mitigating injury from chemical exposure
TWI583404B (zh) * 2015-07-13 2017-05-21 高雄醫學大學 ７,３’,４’-大豆異黃酮製劑的製備方法
WO2018156946A1 (en) * 2017-02-24 2018-08-30 Humanetics Corporation Protecting tissue and mitigating injury from radiation-induced ionizing events
US11129894B2 (en) * 2017-09-29 2021-09-28 - Humanetics Corporation Sensitizing cells to proton radiation
US10881634B2 (en) * 2017-12-07 2021-01-05 Hughes Biotechnology Co., Ltd Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone
US20220193103A1 (en) * 2019-04-23 2022-06-23 The University Of North Carolina At Chapel Hill Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model
WO2021207176A1 (en) * 2020-04-06 2021-10-14 Humanetics Corporation Genistein treatment of inflammatory pulmonary injury
CA3195195A1 (en) * 2020-10-16 2022-05-27 Humanetics Corporation Solid dispersion genistein compositions and methods of making and using the same
US20240058299A1 (en) * 2021-01-11 2024-02-22 Humanetics Corporation Genistein treatment of inflammatory and immunological disorders
CN112843048A (zh) * 2021-04-01 2021-05-28 郑州新泽生物科技有限公司 一种用于抑制雄性动物发情的液体制剂及其制备方法
CN113080365B (zh) * 2021-04-02 2022-12-06 嘉应学院 一种大豆素纳米粉的制备方法及其应用
WO2023177676A1 (en) * 2022-03-14 2023-09-21 University Of South Florida Genistein for asthma treatment
WO2023212130A1 (en) 2022-04-28 2023-11-02 GreenStone Biosciences, Inc. Treatment of the adverse cardiovascular effects of cannabinoids
CN114948869A (zh) * 2022-05-26 2022-08-30 中国药科大学 一种染料木素纳米混悬液的制备方法及该方法制备的染料木素纳米混悬液
WO2025117337A1 (en) 2023-11-28 2025-06-05 GreenStone Biosciences, Inc. Genistein phosphate derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004538242A (ja) * 2000-06-14 2004-12-24 アメリカ合衆国 植物性エストロゲンのイソフラボン組成物、それらの製剤及び放射線傷害に対する防護および処置用のその使用
JP2008544963A (ja) * 2005-06-29 2008-12-11 ディーエスエム アイピー アセッツ ビー．ブイ． イソフラボンナノ粒子およびその使用
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390559A (en) 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
JP2001309764A (ja) 2000-05-01 2001-11-06 Taiyo Kagaku Co Ltd ポリフェノール類組成物
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
ES2254725T3 (es) 2002-06-29 2006-06-16 Aquanova German Solubilisate Technologies (Agt) Gmbh Concentrados de isoflavonas y metodos para su preparacion.
AU2003298659A1 (en) 2002-11-15 2004-06-15 Cargill, Incorporated Soluble isoflavone compositions
WO2005033279A2 (en) 2003-09-29 2005-04-14 University Of Virginia Patent Foundation Discovery of novel soluble crystalline anesthetics
BRPI0512829A (pt) 2004-07-01 2008-04-08 Warner Lambert Co preparação de composições farmacêuticas contendo nanopartìculas
EP1802279A1 (en) 2004-09-29 2007-07-04 Michael Ary Bos Caratenoid composition and method for preparation thereof
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
EA015336B1 (ru) 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Стабильная композиция с наночастицами ацетаминофена
US8685456B2 (en) * 2005-06-29 2014-04-01 Dsm Ip Assets B.V. Topical compositions comprising nanoparticles of an isoflavone
US9743680B2 (en) 2005-10-14 2017-08-29 Wild Flavors, Inc. Microemulsions for use in food and beverage products
US8353639B2 (en) * 2005-11-18 2013-01-15 Deere & Company Turnbuckle lock
WO2008086400A2 (en) * 2007-01-09 2008-07-17 Isp Investments Inc. Sirtuin-activating compounds of enhanced bioavailability
JP2009067752A (ja) 2007-09-14 2009-04-02 Akuto Kk 製剤の製造方法及び製剤
EP2349237A4 (en) 2008-07-31 2012-07-25 Santosh Kumar Kar CURCUMIN NANOTEILS AND MANUFACTURING METHOD THEREFOR
WO2011091065A2 (en) 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
AU2011265184B2 (en) 2010-06-11 2016-08-04 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
US8900635B2 (en) 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
JP5948871B2 (ja) 2011-12-28 2016-07-06 株式会社東洋新薬 ポリフェノール含有組成物
US9084726B2 (en) 2013-11-26 2015-07-21 Humanetics Corporation Suspension compositions of physiologically active phenolic compounds and methods of making and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004538242A (ja) * 2000-06-14 2004-12-24 アメリカ合衆国 植物性エストロゲンのイソフラボン組成物、それらの製剤及び放射線傷害に対する防護および処置用のその使用
JP2008544963A (ja) * 2005-06-29 2008-12-11 ディーエスエム アイピー アセッツ ビー．ブイ． イソフラボンナノ粒子およびその使用
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
難溶性薬物の物性評価と製剤設計の新展開, vol. 第１刷, JPN6015031993, January 2010 (2010-01-01), pages 146 - 150, ISSN: 0003132495 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537430A (ja) * 2013-11-26 2016-12-01 ヒューマネティクス コーポレーション 生理学的に活性なフェノール化合物の懸濁組成物並びにそれを作製及び使用する方法
WO2018168777A1 (ja) * 2017-03-13 2018-09-20 学校法人関西学院 嚢胞性線維症予防又は治療剤
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤

Also Published As

Publication number Publication date
US8551530B2 (en) 2013-10-08
US20170304258A1 (en) 2017-10-26
US20190160038A1 (en) 2019-05-30
US9308167B2 (en) 2016-04-12
US20220370403A1 (en) 2022-11-24
US10039739B2 (en) 2018-08-07
US20150050357A1 (en) 2015-02-19
US10729674B2 (en) 2020-08-04
US20160374984A1 (en) 2016-12-29
US9724325B2 (en) 2017-08-08
US9636322B2 (en) 2017-05-02
EP2640188A1 (en) 2013-09-25
IL226377B (en) 2019-09-26
US20120164190A1 (en) 2012-06-28
US20210000788A1 (en) 2021-01-07
EP2640188B1 (en) 2021-01-06
US20160175276A1 (en) 2016-06-23
CA2852410A1 (en) 2012-05-24
US8900635B2 (en) 2014-12-02
US20120121654A1 (en) 2012-05-17
EP2640188A4 (en) 2014-04-23
IL226377A0 (en) 2013-07-31
CA2852410C (en) 2020-06-30
JP2016074683A (ja) 2016-05-12
JP6181733B2 (ja) 2017-08-16
WO2012068140A1 (en) 2012-05-24
JP2018008967A (ja) 2018-01-18

Similar Documents

Publication Publication Date Title
JP6181733B2 (ja) ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法
Gao et al. Development of a supersaturable SEDDS (S‐SEDDS) formulation of paclitaxel with improved oral bioavailability
US20220133679A1 (en) Efflux inhibitor compositions and methods of treatment using the same
Lim et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors
Peltier et al. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules
KR101721281B1 (ko) 치료제의 미셀 캡슐화
ES2739194T3 (es) Formulación y método para aumentar la biodisponibilidad oral de fármacos
EA015987B1 (ru) Композиция для инъекций, содержащая наночастицы доцетаксела и стабилизатор поверхности
KR20160141776A (ko) 연령 관련 병태를 치료하기 위한 흡입가능한 라파마이신 제제
CN104906044A (zh) 一种癸氧喹酯纳米制剂及其制备方法与应用
US20220273573A1 (en) Solid dispersion genistein compositions and methods of making and using the same
ES2893973T3 (es) Composiciones de múltiples profármacos de aripiprazol
CA2923752A1 (en) Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
JP5329866B2 (ja) 医薬組成物及び関節障害の予防治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150811

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160209